Group 1 - The 2025 Suzhou "Drug Safety Awareness Week" was officially launched with the theme "Drug Safety, Regulation for the People" [1] - The event is organized by the Suzhou Market Supervision Administration and aims to enhance public health literacy and promote drug safety knowledge, particularly for the elderly [1] - Activities include "Medication Safety Classes," mobile promotion stations, and joint medical consultation areas to showcase drug regulation efforts and outcomes [1] Group 2 - The series of promotional activities will continue until September 7 [2]

Group 1 - The "National Drug Safety Publicity Week" will be held from September 1 to 7, 2025, with a series of themed promotional activities organized by the Beijing Drug Administration [1] - Activities will include laboratory open days, public open days, and services delivered to parks and enterprises, aimed at showcasing drug regulation achievements and promoting safety knowledge of drugs, cosmetics, and medical devices [1] - The initiative will involve cross-regional collaboration in the Beijing-Tianjin-Hebei biopharmaceutical sector, exploring innovative regulatory models and hosting national laboratory open day events [1] Group 2 - The "Pharmacist Walks with You" initiative will conduct public lectures in commercial areas and communities, addressing medication safety and management [2] - Over the past five years, Beijing has conducted an average of 13,000 batch inspections annually for drugs, medical devices, and cosmetics, maintaining a drug inspection pass rate of over 99.8% [2] - The "Risk + Credit" classification and grading regulatory system has been upgraded, evaluating 47,000 regulatory entities and identifying over 300 potential risk points [2] Group 3 - Pilot policies for innovative drug clinical review and approval, as well as segmented production of biological products, have been implemented in Beijing [3] - In the innovative drug clinical review pilot, 12 projects have been approved for clinical trials, with the fastest approval taking 18 working days [3] - A green channel for urgently needed imported drugs and devices has been established, benefiting approximately 4,900 patients through the approval of 25 temporary import drug specifications [3]

Group 1 - The core theme of the event is "Drug Safety Regulation for the People," focusing on public awareness and education regarding drug, medical device, and cosmetic safety [1] - Various interactive activities were conducted, including "Safe Medication Science Lecture" and "Verification Technology Open Day," aimed at educating the public about the dangers of antibiotic misuse and promoting safe medication practices [1] - Throughout the event week, diverse promotional and educational activities will be organized by drug regulatory departments, including public open days for drug and cosmetic testing and community outreach programs led by pharmacists [1]

Group 1 - The National Drug Safety Publicity Week was launched on September 1, with activities running until September 7, focusing on public education about drug safety [1] - The theme for the 2025 National Drug Publicity Week is "Drug Safety, Regulation for the People" [1] - In Chongqing, the local drug administration set up four interactive zones with 16 booths, providing free consultations and education on safe medication and cosmetics [1] Group 2 - During the 14th Five-Year Plan period, China conducts over 200,000 drug inspections, 20,000 medical device inspections, and 20,000 cosmetic inspections annually, with a drug inspection pass rate consistently above 99.4% [2] - China's pharmaceutical market ranks second globally, with approximately 30% of innovative drugs under research worldwide [2] - In the first half of 2025, the total amount of foreign licensing for innovative drugs reached nearly $66 billion, indicating increasing global recognition of Chinese innovative drugs [2]

Group 1 - The core theme of the "National Drug Safety Publicity Week" launched by the National Medical Products Administration (NMPA) is "Drug Safety, Regulation for the People" [1] - During the 14th Five-Year Plan period, the demand for medication among the public has been increasingly met, leading to a more stable and consolidated drug safety situation, along with positive innovation in the pharmaceutical industry [1] - Over the past five years, China has approved 210 innovative drugs and 269 innovative medical devices, both showing a trend of accelerated growth [1] Group 2 - China's biopharmaceutical market has become the second largest globally, with approximately 30% of the world's innovative drugs under research [1] - The NMPA has continuously improved the regulatory enforcement system for drugs, conducting special rectification actions and enhancing drug safety measures [1] - The national drug sampling inspection pass rate has remained stable at over 99.4%, effectively ensuring the safety of medications for the public [1]

Group 1 - The core viewpoint emphasizes the importance of drug safety and the comprehensive measures taken during the "14th Five-Year Plan" period to ensure drug safety and support the high-quality development of the pharmaceutical industry [1][3] - The Chinese pharmaceutical industry ranks second globally in terms of scale, indicating significant growth and development potential [3] - A total of 204 innovative drugs and 265 innovative medical devices have been approved, showcasing the country's commitment to innovation in healthcare [3] - Approximately 30% of the innovative drugs under research globally are from China, highlighting the country's increasing role in global pharmaceutical innovation [3] - 27 innovative traditional Chinese medicine drugs have been approved, reflecting the integration of traditional medicine into modern healthcare practices [3]

Group 1 - The core viewpoint emphasizes the importance of drug safety and the comprehensive measures taken during the 14th Five-Year Plan to ensure drug safety and support the high-quality development of the pharmaceutical industry [1][2] - A dynamic regulatory system covering the entire lifecycle of drugs is being established, including a risk consultation mechanism for drug safety [2] - The annual inspection includes over 200,000 batches of various drugs, more than 20,000 batches of medical devices, and over 20,000 batches of cosmetics, ensuring 100% coverage for selected products in national procurement [2] Group 2 - The pharmaceutical industry is receiving full-chain support for high-quality development, with 204 innovative drugs and 265 innovative medical devices approved [4] - The scale of China's pharmaceutical industry ranks among the top globally, with approximately 30% of innovative drugs under research worldwide [4] - Additionally, 27 innovative traditional Chinese medicine drugs have been approved [4]

Market Regulation & Competition - The State Administration for Market Regulation aims to strengthen the domestic market by improving market regulation systems [1] - The focus is on eliminating local protectionism and market segmentation [1] - The administration intends to address unfair competition, specifically targeting the practice of selling substandard products at low prices [1] Product & Equipment Safety - The plan is to enhance the safety supervision capabilities for food, drugs, industrial products, and special equipment [1] - The goal is to strengthen the entire food safety chain, improve drug safety supervision, and raise the quality and safety standards of industrial products [1] - The administration seeks to improve the quality and effectiveness of special equipment safety supervision [1]

Core Viewpoint - The implementation of drug traceability codes in China aims to enhance drug safety and ensure that all drugs involved in centralized procurement have unique electronic identifiers, thereby preventing counterfeit and substandard drugs from entering the market [1][2]. Group 1: Drug Traceability System - Starting from 2025, all drugs participating in centralized procurement must have traceability codes, which serve as unique electronic identities for each drug package [1]. - The traceability system is designed to provide full-chain transparency in drug management, ensuring that the source, destination, and accountability of drugs can be tracked [2]. - As of February 2025, the National Medical Insurance Information Platform has collected 21.936 billion traceability codes, covering all 31 provinces in China [2]. Group 2: Impact on Drug Safety - The "code-based procurement" approach has effectively reduced drug quality risks and has led to the identification and punishment of illegal activities such as drug reselling and swapping [2]. - The "code-based settlement" mechanism has facilitated precise supervision of medical insurance funds, recovering 27.5 billion yuan in fraudulent claims and identifying 2,008 fraudulent institutions [2]. Group 3: Challenges and Recommendations - Despite advancements, there are still weaknesses in drug safety management, particularly in post-market supervision and the classification of different drug types [3]. - The need for a refined classification and grading management system for various drug types, especially high-risk drugs, is emphasized to prevent treatment failures and adverse reactions [3]. - Recommendations include enhancing the drug traceability system, training specialized personnel, and establishing comprehensive legal frameworks to support the system [5].

Core Points - The new regulation mandates that from July 1, 2023, medical institutions must scan drug traceability codes before settling with medical insurance funds, enhancing drug safety [1] - By January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes, establishing a comprehensive tracking system for pharmaceuticals [1] - The traceability code acts as a unique electronic identity for each drug, ensuring that each box of medication has a single sales record, thus preventing counterfeit and swapped drugs [1] Industry Impact - The integration of drug traceability codes with medical insurance is significant for public drug safety, effectively combating issues like "returned drugs" and fraudulent transactions [2] - The traceability system allows for precise monitoring of high-priced drugs, ensuring they are used appropriately and reach the patients in need [2] - The National Medical Insurance Administration has already demonstrated the effectiveness of this system by investigating the traceability codes of specific drugs, thereby safeguarding both drug safety and insurance funds [2] Public Engagement - Consumers are encouraged to actively participate in ensuring their own drug safety by following six key practices when purchasing medications, including verifying the presence of traceability codes and scanning them for authenticity [3] - The promotion of drug traceability codes is essential, with the goal of making the scanning process a standard practice in every drug transaction [3] - Strengthening regulatory measures around drug traceability codes will help close potential loopholes and enhance public health protection [3]